...
首页> 外文期刊>Genome Biology >SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing.
【24h】

SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing.

机译:SHROOM3是通过全外显子组测序鉴定出的新型异位候选物。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Heterotaxy-spectrum cardiovascular disorders are challenging for traditional genetic analyses because of clinical and genetic heterogeneity, variable expressivity, and non-penetrance. In this study, high-resolution SNP genotyping and exon-targeted array comparative genomic hybridization platforms were coupled to whole-exome sequencing to identify a novel disease candidate gene. RESULTS: SNP genotyping identified absence-of-heterozygosity regions in the heterotaxy proband on chromosomes 1, 4, 7, 13, 15, 18, consistent with parental consanguinity. Subsequently, whole-exome sequencing of the proband identified 26,065 coding variants, including 18 non-synonymous homozygous changes not present in dbSNP132 or 1000 Genomes. Of these 18, only 4--one each in CXCL2, SHROOM3, CTSO, RXFP1--were mapped to the absence-of-heterozygosity regions, each of which was flanked by more than 50 homozygous SNPs, confirming recessive segregation of mutant alleles. Sanger sequencing confirmed the SHROOM3 homozygous missense mutation and it was predicted as pathogenic by four bioinformatic tools. SHROOM3 has been identified as a central regulator of morphogenetic cell shape changes necessary for organogenesis and can physically bind ROCK2, a rho kinase protein required for left-right patterning. Screening 96 sporadic heterotaxy patients identified four additional patients with rare variants in SHROOM3. CONCLUSIONS: Using whole exome sequencing, we identify a recessive missense mutation in SHROOM3 associated with heterotaxy syndrome and identify rare variants in subsequent screening of a heterotaxy cohort, suggesting SHROOM3 as a novel target for the control of left-right patterning. This study reveals the value of SNP genotyping coupled with high-throughput sequencing for identification of high yield candidates for rare disorders with genetic and phenotypic heterogeneity.
机译:背景:由于临床和遗传异质性,可变表达性和非穿透性,异质谱心血管疾病对传统的遗传分析具有挑战性。在这项研究中,高分辨率SNP基因分型和以外显子为靶点的阵列比较基因组杂交平台与全外显子测序结合,以鉴定新的疾病候选基因。结果:SNP基因分型鉴定出杂种先证者在1、4、7、13、15、18号染色体上没有杂合性区域,这与父母的血缘性一致。随后,先证者的全外显子组测序鉴定出26,065个编码变体,包括dbSNP132或1000个基因组中不存在的18个非同义纯合变化。在这18个中,仅将CXCL2,SHROOM3,CTSO和RXFP1中的4个一一映射到不存在杂合子的区域,每个区域的侧翼均超过50个纯合SNP,证实了突变等位基因的隐性分离。 Sanger测序证实了SHROOM3纯合的错义突变,并通过四种生物信息学工具预测为致病性。 SHROOM3已被确定为器官发生所必需的形态发生细胞形状变化的中央调节剂,可以与ROCK2物理结合,ROCK2是左右构图所需的rho激酶蛋白。筛选了96例散发性异位症患者,确定了另外4名SHROOM3罕见变异患者。结论:使用完整的外显子组测序,我们确定SHROOM3中的隐性错义突变与异型症候群相关联,并在随后的异源性队列筛选中鉴定出罕见的变异体,表明SHROOM3是控制左右模式的新型靶标。这项研究揭示了SNP基因分型与高通量测序在鉴定具有遗传和表型异质性的罕见疾病的高产候选基因中的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号